Protagonist Therapeutics, Inc. News Releases http://investors.protagonist-inc.com/ Protagonist Therapeutics, Inc. News Releases en Protagonist Therapeutics Reports Granting of Inducement Award http://investors.protagonist-inc.com/news-releases/news-release-details/protagonist-therapeutics-reports-granting-inducement-award-5 NEWARK, Calif. , June 18, 2019 /PRNewswire/ --  Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on June 17, 2019 , it issued an inducement award to Nishit Modi , Ph.D., the Company's recently hired Vice President of Clinical Pharmacology, in accordance with the terms of Dr. Tue, 18 Jun 2019 16:30:00 -0400 Protagonist Therapeutics, Inc. News Releases 8281 Protagonist Therapeutics to Present at the BMO 2019 Prescription for Success Healthcare Conference http://investors.protagonist-inc.com/news-releases/news-release-details/protagonist-therapeutics-present-bmo-2019-prescription-success NEWARK, Calif. , June 17, 2019 /PRNewswire/ --  Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that David Liu , Ph.D., Chief Scientific Officer and Head of Research and Development, will provide a corporate overview at the BMO 2019 Prescription for Success Healthcare Conference in New Mon, 17 Jun 2019 07:00:00 -0400 Protagonist Therapeutics, Inc. News Releases 8266 Protagonist Therapeutics Reports Granting of Inducement Award http://investors.protagonist-inc.com/news-releases/news-release-details/protagonist-therapeutics-reports-granting-inducement-award-4 NEWARK, Calif. , June 4, 2019 /PRNewswire/ --  Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on May 31, 2019 , it issued an inducement award to Don Kalkofen , the Company's recently hired Chief Financial Officer, in accordance with the terms of Mr. Tue, 04 Jun 2019 07:00:00 -0400 Protagonist Therapeutics, Inc. News Releases 8226 Protagonist Therapeutics Appoints Don Kalkofen as Chief Financial Officer http://investors.protagonist-inc.com/news-releases/news-release-details/protagonist-therapeutics-appoints-don-kalkofen-chief-financial NEWARK, Calif. , May 29, 2019 /PRNewswire/ --  Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced the appointment of Don Kalkofen as Chief Financial Officer. Mr. Kalkofen brings over 29 years of finance and corporate management experience to the company. "Mr. Wed, 29 May 2019 16:30:00 -0400 Protagonist Therapeutics, Inc. News Releases 8206 Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Superior Dose-Related Target Engagement Activity to PTG-100 in Single Ascending Dose Phase 1 Study http://investors.protagonist-inc.com/news-releases/news-release-details/oral-alpha-4-beta-7-integrin-antagonist-pn-943-demonstrates -- PN-943 was safe and well tolerated with gut-restricted exposure -- -- Pharmacodynamic data for PN-943 in healthy volunteers confirm higher potency observed in preclinical studies versus PTG-100 -- NEWARK, Calif. , May 14, 2019 /PRNewswire/ --  Protagonist Therapeutics, Inc. Tue, 14 May 2019 07:00:00 -0400 Protagonist Therapeutics, Inc. News Releases 8186 Protagonist Therapeutics Reports First Quarter 2019 Financial Results http://investors.protagonist-inc.com/news-releases/news-release-details/protagonist-therapeutics-reports-first-quarter-2019-financial -- PTG-200 collaboration agreement with Janssen Biotech expanded to include second generation oral IL-23 receptor antagonists; expanded agreement triggers $25 million milestone payment to Protagonist -- -- Protagonist appoints Samuel Saks, M.D., as Chief Medical Officer and Suneel Gupta, Ph.D., as Wed, 08 May 2019 07:01:00 -0400 Protagonist Therapeutics, Inc. News Releases 8156 Protagonist Therapeutics Expands PTG-200 Collaboration Agreement with Janssen to Include Second Generation Oral IL-23 Receptor Antagonists http://investors.protagonist-inc.com/news-releases/news-release-details/protagonist-therapeutics-expands-ptg-200-collaboration-agreement -- Protagonist receives a $25 million payment -- -- Janssen to advance PTG-200 forward to Phase 2 Crohn's study -- -- Under amended terms Protagonist is now eligible for total milestones in excess of $1 billion and tiered royalty payments on net sales -- -- Management to host conference call May 8, Wed, 08 May 2019 07:00:00 -0400 Protagonist Therapeutics, Inc. News Releases 8151 Protagonist Therapeutics to Present Preclinical Data on PN-943 at Digestive Disease Week Conference 2019 http://investors.protagonist-inc.com/news-releases/news-release-details/protagonist-therapeutics-present-preclinical-data-pn-943 -- Oral plenary presentation to detail properties of oral, gut-restricted alpha-4-beta-7 integrin antagonist candidate PN-943 -- NEWARK, Calif. , May 7, 2019 /PRNewswire/ --  Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that Larry Mattheakis, Ph.D., SVP Discovery Biology and Tue, 07 May 2019 07:00:00 -0400 Protagonist Therapeutics, Inc. News Releases 8146 Protagonist Therapeutics to Present at the H.C. Wainwright & Co. Global Life Sciences Conference on Tuesday, April 9 http://investors.protagonist-inc.com/news-releases/news-release-details/protagonist-therapeutics-present-hc-wainwright-co-global-life NEWARK, Calif. , April 1, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that Dinesh V. Patel , Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright & Co. Global Life Sciences Conference in London . Mon, 01 Apr 2019 07:00:00 -0400 Protagonist Therapeutics, Inc. News Releases 8091 Protagonist Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results http://investors.protagonist-inc.com/news-releases/news-release-details/protagonist-therapeutics-reports-fourth-quarter-and-full-year -- Preliminary results from the Phase 2 TRANSCEND study of the hepcidin mimetic PTG-300 for the treatment of beta thalassemia expected in the second half of 2019 -- -- U.S. Investigational New Drug (IND) filing by Janssen to support a Phase 2 study of oral IL-23 receptor antagonist PTG-200 Tue, 12 Mar 2019 16:01:00 -0400 Protagonist Therapeutics, Inc. News Releases 8061